Overview

Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

Status:
Recruiting

Trial end date:
2024-09-20

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus lenvatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Lenvatinib